Substrate interaction with 5α-reductase enzyme: Influence of the 17β-chain chirality in the mechanism of action of 4-azasteroid inhibitors

Steroids

Volumn 66, Issue 11, 2001, Pages 803-810

  Grisenti, Paride ^a   Magni, Ambrogio ^a   Olgiati, Vincenzo ^a   Manzocchi, Ada ^b   Ferraboschi, Patrizia ^b   Villani, Vincenzo ^c   Pucciariello, Rachele ^c   Celotti, Fabio ^b  

^a Poli Industria Chimica SpA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF BASILICATA   (Italy)

Author keywords

4 Azasteroids; Biological activity; Chirality; Inhibitors; Molecular modeling; reductase; Testosterone 5

Indexed keywords

4 AZASTEROID; FINASTERIDE; N (ALPHA METHYLBENZYL) 4 METHYL 3 OXO 4 AZA 5ALPHA ANDROSTANE 17BETA CARBOXAMIDE; N (LEUCYL ETHYL ESTER) 4 METHYL 3 OXO 4 AZA 5ALPHA ANDROSTANE 17BETA CARBOXAMIDE; N (LEUCYL METHYL AMIDE) 4 METHYL 3 OXO 4 AZA 5ALPHA ANDROSTANE 17BETA CARBOXAMIDE; N (PHENYLALANYL METHYL AMIDE) 4 METHYL 3 OXO 4 AZA 5ALPHA ANDROSTANE 17BETA CARBOXAMIDE; N GLYCINYL 3 OXO 4 AZA 5ALPHA ANDROSTANE 17BETA CARBOXAMIDE; STEROID; STEROID 5ALPHA REDUCTASE; STEROID 5ALPHA REDUCTASE INHIBITOR; UNCLASSIFIED DRUG; ENZYME INHIBITOR; ISOENZYME;

ARTICLE; BINDING SITE; COMPUTER MODEL; COMPUTER PROGRAM; DIASTEREOISOMER; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME BINDING; ENZYME INHIBITION; IN VITRO STUDY; INFRARED SPECTROPHOTOMETRY; LIPOPHILICITY; MASS SPECTROMETRY; MODEL; NUCLEAR MAGNETIC RESONANCE; PROSTATE; RADIOENZYMATIC ASSAY; STRUCTURE ACTIVITY RELATION; ANIMAL; BIOLOGICAL MODEL; CONFORMATION; DRUG ANTAGONISM; DRUG DESIGN; METABOLISM; PHYSIOLOGY; RAT; SYNTHESIS;

ANIMALS; BINDING SITES; DRUG DESIGN; ENZYME INHIBITORS; ISOENZYMES; MODELS, BIOLOGICAL; MOLECULAR CONFORMATION; RATS; STEROIDS; STRUCTURE-ACTIVITY RELATIONSHIP; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 0034741613     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-128X(01)00114-3     Document Type: Article

References (25)

1. Azasteroids as inhibitors of rat prostatic 5α- reductase
2. Azasteroids; structure-activity relationships for inhibition of 5α-reductase, and of androgen receptor binding
3. Steroidal A ring aryl carboxylic acids; a new class of steroid 5α-reductase inhibitors
4. Selective retention of dihydrotestosterone by prosthetic nuclei
5. The conversion of testosterone to 5α- androstan-17β-ol-3-one by rat prostate in vivo and in vitro
6. Inhibitors of steroid 5α- reductase in benign prostatic hyperplasia, male pattern baldness and acne
7. Steroid 5α-reductase; two genes/two enzymes
8. Tissue distribution and kinetic characteristics of rat steroid 5α-reductase isozymes
9. Benzophenone- and indolecarboxylic acids. Potent type-2 specific inhibitors of human steroid 5α- reductase
10. Nonsteroidal inhibitors of human type I steroid 5α-reductase
11. 5-steroid isomerase
12. Four-amino acid segment in steroid 5α- reductase 1 confers sensitivity to finasteride, a competitive inhibitor
13. 17β-(N-tert-Butylcarbamoyl)-4-aza-5α-androstan-1-en-3-one is an active site-directed slow time-dependent inhibitor of human steroid 5α-reductase 1
14. 4,7β-Dimethyl-4-azacholestan-3-one (MK-386) and related 4-azasteroids as selective inhibitors of human type I 5α-reductase
15. On the three dimensional Wiener number
16. Pharmacological options in the treatment of benign prostatic hyperplasia
17. Characterisation of rat 5α- reductase type 1 and type 2 expressed in Saccharomyces cerevisiae
18. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
19. Stereoselectivity and affinity in molecular pharmacology
20. Atomic physicochemical parameters for three dimensional structure directed quantitative structure-activity relationships III; modeling hydrophobic interactions
21. The calculation of molecular volumes and the use of volume analysis in the investigation of structured media and of solid-state organic reactivity